Shitij Kapur

Shitij Kapur

Auto-generated profile, based on publicly available information

Shitij Kapur

Institute of Psychiatry, King's College London, London, UK

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

30 March 2009 in Schizophrenia Bulletin
Verified
Journal Article
Closed access
OHO. D. Howes
O. D. Howes
SKS. Kapur
S. Kapur
The dopamine hypothesis of schizophrenia has been one of the most enduring ideas in psychiatry. Initially, the emphasis was on a role of hyperdopaminergia in the etiology of schizophrenia (version I), but it was subsequently reconceptualized to specify subcortical hyperdopaminergia with prefrontal hypodopaminergia (version II). However, these hypotheses focused too narrowly on dopamine itself, conflated psychosis and schizophrenia, and predated advances in the genetics, molecular biology, and imaging research in schizophrenia. Since version II, there have been over 6700 articles about dopamine and schizophrenia. We selectively review these data to provide an overview of the 5 critical streams of new evidence: neurochemical imaging studies, genetic evidence, findings on environmental risk factors, research into the extended phenotype, and animal studies. We synthesize this evidence into a new dopamine hypothesis of schizophrenia-version III: the final common pathway. This hypothesis seeks to be comprehensive in providing a framework that links risk factors, including pregnancy and obstetric complications, stress and trauma, drug use, and genes, to increased presynaptic striatal dopaminergic function. It explains how a complex array of pathological, positron emission tomography, magnetic resonance imaging, and other findings, such as frontotemporal structural and functional abnormalities and cognitive impairments, may converge neurochemically to cause psychosis through aberrant salience and lead to a diagnosis of schizophrenia. The hypothesis has one major implication for treatment approaches. Current treatments are acting downstream of the critical neurotransmitter abnormality. Future drug development and research into etiopathogenesis should focus on identifying and manipulating the upstream factors that converge on the dopaminergic funnel point.

1 August 2009 in The Lancet
Verified
Journal Article
Closed access
JOJim van Os
Jim van Os
SKShitij Kapur
Shitij Kapur

6 July 2011 in Nature
Verified
Journal Article
Open access
PDF file
PCPamela Y. Collins
Pamela Y. Collins
VPVikram Patel
Vikram Patel
SJSarah S. Joestl
Sarah S. Joestl
DMDana March
Dana March
TIThomas R. Insel
Thomas R. Insel
MWMark Walport
Mark Walport
A consortium of researchers, advocates and clinicians announces here research priorities for improving the lives of people with mental illness around the world, and calls for urgent action and investment.

7 August 2012 in Molecular Psychiatry
Verified
Journal Article
Closed access
SKS Kapur
S Kapur
APA G Phillips
A G Phillips
TIT R Insel
T R Insel

1 April 2000 in American Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
SKShitij Kapur
Shitij Kapur
RZRobert Zipursky
Robert Zipursky
CJCorey Jones
Corey Jones
GRGary Remington
Gary Remington
SHSylvain Houle
Sylvain Houle